--

Mr Bhaskar Gupta is a Consultant Ophthalmologist at University Hospital Southampton NHS Trust. He sees private patients at the following locations:

• Spire Southampton Hospital
• Optegra Eye Hospital Surrey
• Opetgra Eye Hospital Hampshire

He has a special interest in vitreoretinal disorders including macular hole, epiretinal membrane, floaters, cataracts, diabetic retinopathy, and macular degeneration. He also sub-specialises in the treatment of retinal conditions, including:

• Catarat
• Macular Hole
• Complex diabetic eye disease
• Retinal detachment
• Epiretinal membrane
• Vitreous floaters
• YAG Laser

Mr Gupta received his medical degree in 2001 from B. J. Medical College in Ahmedabad, India, and went on to pursue a master's degree in ophthalmology from the same university, earning a Gold Medal. He then undertook a higher research degree (DM) from Cranfield University in the United Kingdom, where he investigated racial differences in diabetic retinopathy. In 2015, he finished his specialty ophthalmology training in the U.L. with the South West Peninsula Deanery. Following that, he completed two years of sub-specialty training in vitreoretinal disease at the Royal Berkshire Hospital and University Hospital Southampton.

Over the course of his career, Mr Gupta has performed almost 12500 cataract surgeries and almost 1500 vitrectomies. He is an experienced high volume cataract surgeon with excellent results.

He is also involved in charitable work and supports Khmer Sight, Cambodia and BKL Walawalkar Charitable Trust, India, where he teaches and performs cataract surgery. Additionally, he is currently trying to set up diabetic screening services in these areas.

He is actively involved in clinical research and lead Research for vitreo-retina services at University Hospital Southampton. He is Principal Investigator for EVIAN study (Early Vitrectomy and Intravitral Antibiotics for post operative exogenous endophthalmitis) a sight threatening infection after any intraocular surgery, TIGER study (Vitrectomy and subretinal therapy in patients with Wet MAcular degeration), DIAGRID (Commercial trial looking at new Port Delivery Sysytem to deliver sustained Anti-VEGF drugs in eyes with WET AMD. Also approved centre for gene therapy in patients with macular degeration and atrophy